Registered outcomes12

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

1 to 12 of 12

List	Outcome	Time frame	Description
Primary	Evaluate the long-term efficacy of vosoritide treatment until final adult height (FAH)	Annually from enrollment through Final Adult Height, defined as 16 years of age for females and 18 years of age for males	As measured by change from baseline in height Z-score
Secondary	Evaluate the maintenance effect of vosoritide treatment on standing height	Baseline to week 52	change from baseline in height at Week 52
Secondary	Evaluate the maintenance effect of vosoritide treatment on standing height Z-score	Baseline to week 52	Change from baseline in height Z-score at Week 52
Secondary	Evaluate long-term effect of vosoritide treatment on growth velocity	Annually from enrollment through Final Adult Height, defined as 16 years of age for females and 18 years of age for males	Absolute 6- or 12-month interval AGV
Secondary	Evaluate long-term effect of vosoritide treatment on body proportionality	Annually from enrollment through Final Adult Height, defined as 16 years of age for females and 18 years of age for males	Change from baseline in upper to lower body segment ratio
Secondary	Evaluate long-term effect of vosoritide treatment on bone age versus chronological age	Annually from enrollment through Final Adult Height, defined as 16 years of age for females and 18 years of age for males	As measured by left-hand and wrist x-ray
Secondary	Evaluate long-term effect of vosoritide treatment on bone metabolism biomarkers	Annually from enrollment through Final Adult Height, defined as 16 years of age for females and 18 years of age for males	Change from baseline in serum collagen X marker
Secondary	Evaluate long-term changes in Health-Related Quality of Life (HRQoL)	Annually from enrollment through Final Adult Height, defined as 16 years of age for females and 18 years of age for males	Change from baseline as measured by Quality of Life In Short-Statured Youth (QoLISSY) total score
Secondary	Evaluate long-term effect of vosoritide treatment on bone quality	Annually from enrollment through Final Adult Height, defined as 16 years of age for females and 18 years of age for males	Change from baseline in bone mineral density (BMD) as measured by Dual X-Ray Absorptiometry
Secondary	Evaluate long-term effect of vosoritide treatment on pubertal growth as measured by Tanner Staging	Annually from enrollment through Final Adult Height, defined as 16 years of age for females and 18 years of age for males
Secondary	To monitor the incidence of otitis media	Annually from enrollment through Final Adult Height, defined as 16 years of age for females and 18 years of age for males
Secondary	To monitor the frequency of seizures	Annually from enrollment through Final Adult Height, defined as 16 years of age for females and 18 years of age for males

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT07073014/registered

API reference For AI assistants